{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:16:17Z","timestamp":1781795777021,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jtct.2022.07.007","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T02:46:14Z","timestamp":1657593974000},"page":"358.e1-358.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4086-6453","authenticated-orcid":false,"given":"Qaiser","family":"Bashir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo C.","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3799-681X","authenticated-orcid":false,"given":"Michael J.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Anasetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Brunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9567-0805","authenticated-orcid":false,"given":"Peter","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Efebera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gasparetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0500-7386","authenticated-orcid":false,"given":"Nancy","family":"Geller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aric C.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Koreth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Stadtmauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7721-3870","authenticated-orcid":false,"given":"David H.","family":"Vesole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8800-297X","authenticated-orcid":false,"given":"Parameswaran","family":"Hari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.07.007_bib0001","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.07.007_bib0002","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2022.07.007_bib0003","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1200\/JCO.2010.29.7929","article-title":"International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma","volume":"28","author":"Lokhorst","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.07.007_bib0004","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.07.007_bib0005","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fonc.2017.00287","article-title":"Allograft for myeloma: examining pieces of the jigsaw puzzle","volume":"7","author":"Malek","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2022.07.007_bib0006","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.007_bib0007","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","article-title":"Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma","volume":"100","author":"Kr\u00f6ger","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.007_bib0008","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.07.007_bib0009","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.bbmt.2019.11.018","article-title":"Tandem autologous-autologous versus autologous-allogeneic hematopoietic stem cell transplant for patients with multiple myeloma: long-term follow-up results from the Blood and Marrow Transplant Clinical Trials Network 0102 trial","volume":"26","author":"Giralt","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.007_bib0010","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2010-10-300970","article-title":"Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2","volume":"117","author":"Munshi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.007_bib0011","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/leu.2017.331","article-title":"Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time","volume":"32","author":"Kumar","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.07.007_bib0012","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.bbmt.2013.02.003","article-title":"Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation","volume":"19","author":"Nishihori","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.007_bib0013","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1038\/s41375-020-0830-0","article-title":"Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era","volume":"34","author":"Dhakal","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.07.007_bib0014","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.bbmt.2020.07.005","article-title":"Ixazomib for chronic graft-versus-host disease prophylaxis following allogeneic hematopoietic cell transplantation","volume":"26","author":"Chhabra","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.007_bib0015","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3324\/haematol.2017.176859","article-title":"Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results","volume":"103","author":"Koreth","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.07.007_bib0016","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2022.07.007_bib0017","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/bmt.2013.37","article-title":"Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma","volume":"48","author":"Nishihori","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.007_bib0018","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2011-04-348292","article-title":"Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial","volume":"118","author":"Kneppers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.007_bib0019","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.bbmt.2014.04.014","article-title":"Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation","volume":"20","author":"Alsina","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.007_bib0020","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.07.007_bib0021","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.07.007_bib0022","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group","volume":"27","author":"Fern\u00e1ndez de Larrea","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.07.007_bib0023","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/rssa.12250","article-title":"Estimating the cumulative incidence function of dynamic treatment regimens","volume":"181","author":"Yavuz","year":"2016","journal-title":"J R Stat Soc A Stat."},{"key":"10.1016\/j.jtct.2022.07.007_bib0024","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2141.2012.09099.x","article-title":"Bortezomib salvage followed by a phase I\/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma","volume":"157","author":"Nishihori","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.07.007_bib0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2009-06-229658","article-title":"Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)","volume":"115","author":"Roussel","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.007_bib0026","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1158\/1078-0432.CCR-10-1662","article-title":"A phase I\/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study","volume":"16","author":"Lonial","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2022.07.007_bib0027","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2009-07-231092","article-title":"Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors","volume":"114","author":"Koreth","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.007_bib0028","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1200\/JCO.2012.42.0984","article-title":"Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation","volume":"30","author":"Koreth","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.07.007_bib0029","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2141.2007.06921.x","article-title":"Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2","volume":"140","author":"Pineda-Roman","year":"2008","journal-title":"Br J Haematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722014671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722014671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:09:42Z","timestamp":1763003382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722014671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2666636722014671"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.07.007","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}